MARKET

VERO

VERO

Venus Concept Inc
NASDAQ
0.7997
-0.0403
-4.80%
Opening 10:06 04/19 EDT
OPEN
0.7649
PREV CLOSE
0.8400
HIGH
0.7997
LOW
0.7649
VOLUME
5.16K
TURNOVER
0
52 WEEK HIGH
4.700
52 WEEK LOW
0.6015
MARKET CAP
5.08M
P/E (TTM)
-0.1168
1D
5D
1M
3M
1Y
5Y
VENUS CONCEPT- ON APRIL 11, GOT NOTICE FROM NASDAQ THAT CO’S COMMON STOCK DID NOT MAINTAIN MINIMUM CLOSING BID PRICE REQUIRED FOR CONTINUED LISTING
Reuters · 1d ago
Weekly Report: what happened at VERO last week (0408-0412)?
Weekly Report · 4d ago
Venus Concept to Release First Quarter of Fiscal Year 2024 Financial Results on May 15, 2024
Venus Concept's first quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday, May 15, 2024. The company is a global medical aesthetic technology leader. Venus Concept is a subsidiary of Venus Concept Inc. The company's shares will be listed on Nasdaq.
Barchart · 4d ago
Venus Concept files to sell 1.64M shares of common stock for holders
Venus Concept files to sell 1.64M shares of common stock for holders. Venus Concept (NASDAQ:VERO) filed a prospectus related to the resale by the selling stockholders of up to 1,644,400 shares. This prospectus is not an offer to sell.
Seeking Alpha · 04/08 21:29
VENUS CONCEPT -FILES PROSPECTUS RELATES TO RESALE, FROM TIME TO TIME, BY SELLING STOCKHOLDERS OF UP TO 1.6 MLN SHARES OF COMMON STOCK
Reuters · 04/08 21:21
Venus Concept gets approval from Israel regulators for Venus Bliss MAX
Venus Concept gets approval from Israel regulators for Venus Bliss MAX. The company's shares rose 3% in pre-market trade. Venus Concept first launched the Venus BlissMAX commercially in the U.S. In Q1 2022. The company got approval from the State of Israel Ministry of Health.
Seeking Alpha · 04/08 11:43
Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAX
Venus Concept has received approval for the Venus Bliss MAX from the State of Israel Ministry of Health. The Venus BlissMAX will be first launched commercially in the United States in Q1 2022. The company is a global medical aesthetic technology leader. The company has received FDA 510(k) clearance.
Benzinga · 04/08 11:31
VENUS CONCEPT INC: HAS RECEIVED APPROVAL FOR VENUS BLISS MAX FROM STATE OF ISRAEL MINISTRY OF HEALTH
Reuters · 04/08 11:30
More
About VERO
Venus Concept Inc. is a global medical aesthetic technology company. The Company has a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches in over 60 countries and 14 direct markets. The Company's product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve, Venus Viva MD and AI.ME. Its hair restoration systems include NeoGraft and the ARTAS iX Robotic Hair Restoration system. The Company's systems are designed on flexible platforms that enable it to expand beyond the aesthetic industry's traditional markets of dermatology and plastic surgery, and into non-traditional markets, including family and general practitioners and aesthetic medical spas. The Company's hair loss treatment solutions include the ARTAS Solution and the NeoGraft Solution.

Webull offers Venus Concept Inc stock information, including NASDAQ: VERO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VERO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VERO stock methods without spending real money on the virtual paper trading platform.